Molecular Signatures in Inflammatory Skin Disease

NCT03358693 · clinicaltrials.gov ↗

RECRUITING

Status

300

Enrollment

OTHER

Sponsor class

Conditions

Atopic Dermatitis
Psoriasis

Interventions

DRUG: Anti-TNF
DRUG: Anti-IL12/23
DRUG: Anti-IL17
DRUG: Dupilumab
DRUG: Anti-IL23
DRUG: Baricitinib
DRUG: Abrocitinib
DRUG: Upadacitinib
DRUG: Tralokinumab
DRUG: Lebrikizumab
DRUG: Nemolizumab

Sponsor

Prof. Dr. Stephan Weidinger